The BMA and Mounjaro: separating the position from the myths

The biggest misconception: BMA concern as evidence that Mounjaro is unsafe or unproven

The thing our prescribers hear most frequently from people who've read headlines about the BMA is some version of: "Doctors are against it, so maybe I shouldn't." It's a reasonable first reaction and worth unpicking calmly.

The BMA's statements on GLP-1 medicines, including tirzepatide, have been directed at the NHS rollout, the pace, the infrastructure, the risk that patients start treatment without adequate dietary support or follow-up. Those are legitimate system-level concerns. They are not a verdict on whether tirzepatide works or whether it is safe.

Mounjaro received its UK marketing authorisation through the MHRA, the body that actually licenses medicines. NICE then appraised the evidence in detail and recommended it in December 2024, concluding that the clinical data supported its use for eligible adults with obesity. The BMA does not have the statutory role of approving or withdrawing medicines, that sits with the MHRA. So when a BMA spokesperson calls for "caution" or "better oversight," they are speaking as a professional body about how care is organised, not challenging the medicine's status. Those are different conversations, and conflating them causes real confusion for patients trying to make an informed decision.

What the BMA has actually said, and the professional context behind it

The BMA's interventions around GLP-1 medicines have tended to focus on two areas: the risk of prescribing these medicines without proper clinical assessment, and the strain on GP time as demand rises sharply. Both points are grounded in genuine clinical governance concerns rather than opposition to the medicines themselves.

On clinical assessment: the BMA has been clear that patients should be assessed by a qualified clinician before starting tirzepatide or semaglutide. This aligns precisely with how the medicines are legally classified. These are prescription-only medicines, a prescriber has to review your individual circumstances, your health history, any other medicines you take, and whether the benefit outweighs any risk for you specifically. A responsible private provider operates on exactly this basis.

On GP capacity: NHS practices began prescribing tirzepatide under the new GP contract from April 2026, and many GPs have flagged that demand is outpacing the time available for the kind of structured support NICE recommends alongside prescribing. That concern belongs to the NHS access debate, not to whether private, clinically supervised prescribing is appropriate. You can read more about how NHS and private routes compare on our Mounjaro treatment overview.

Understanding this context (that the BMA is commenting on infrastructure rather than the medicine) changes how you read the headlines considerably.

How clinical governance applies to private prescribing of Mounjaro

One thread running through the BMA's statements is that robust clinical oversight matters wherever these medicines are prescribed: NHS or private. That is hard to argue with. The question is what good oversight looks like in practice.

At a minimum it means a qualified prescriber reviews the patient (not a questionnaire scoring algorithm) before any prescription is issued. It means identity and current weight are verified, not taken on trust. It means relevant medical history is considered, including whether any conditions or medicines interact with tirzepatide. The NHS tirzepatide medicines page outlines the key safety considerations in plain language, and they are the same whether prescribing happens inside the NHS or through a regulated private service.

It also means ongoing review. Starting at 2.5mg and moving through the licensed dose range over several months is not a "set and forget" process, and if you want a closer look at how that titration works in practice, the Mounjaro dose guidance covers the 2.5mg starting point and what comes next. That kind of structured follow-up is what separates legitimate clinical practice from the kind of unmonitored supply the BMA is right to worry about.

If you want to understand the cost picture before committing to private treatment, the Mounjaro pricing page sets out what a complete, clinically supervised private service typically involves. The tirzepatide mechanism (it acts on both GLP-1 and GIP receptors, which is why it is sometimes described as a dual agonist) is covered in more depth on the tirzepatide explainer.

Eligibility and where the BMA's position leaves patients considering Mounjaro

NICE's recommendation (TA1026) covers adults with a BMI of 35 or above and at least one qualifying weight-related condition: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. For some ethnic backgrounds, the threshold is 2.5 kg/m² lower. Separately, the medicine's marketing authorisation permits prescribing from a BMI of 30, or 27 with a relevant condition, so private clinical assessment can lawfully take in a wider group than the NHS currently treats. The BMJ's coverage of Mounjaro offers a useful independent perspective on how the evidence has been received across the medical community, and the BMS position on Mounjaro adds further professional context for anyone weighing up the clinical picture.

The BMA's position does not change any of that. What it reinforces is that the clinical assessment step should be real and thorough. A prescriber who spends 30 seconds on a submitted questionnaire is the target of the BMA's concern. A prescriber who reads your full health history, checks for contraindications, verifies your weight, and follows your progress over time is doing exactly what the medical profession (including the BMA) would want.

Our clinical team reviews every consultation personally, and every repeat order is clinically re-assessed before any treatment is dispatched. If you have questions about whether Mounjaro is likely to be suitable for your situation, the FAQs page covers some of the most common ones, and the free consultation is the place to get an answer specific to you. Check your eligibility there, it costs nothing and the clinical review happens the same day.